Capital International Ltd. CA Has $18.29 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Capital International Ltd. CA lifted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 93.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 204,736 shares of the medical equipment provider's stock after acquiring an additional 98,646 shares during the quarter. Capital International Ltd. CA's holdings in Boston Scientific were worth $18,287,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in BSX. Parnassus Investments LLC lifted its position in shares of Boston Scientific by 0.7% in the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock valued at $1,327,000 after buying an additional 97 shares during the last quarter. Evergreen Capital Management LLC lifted its holdings in Boston Scientific by 1.7% during the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after purchasing an additional 106 shares during the last quarter. PDS Planning Inc boosted its position in Boston Scientific by 1.5% during the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after purchasing an additional 113 shares during the period. Adero Partners LLC increased its holdings in shares of Boston Scientific by 3.3% in the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after purchasing an additional 120 shares during the last quarter. Finally, Grove Bank & Trust raised its position in shares of Boston Scientific by 4.4% in the fourth quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after purchasing an additional 122 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Trading Up 5.1 %

NYSE BSX traded up $4.81 on Wednesday, reaching $99.86. The company had a trading volume of 6,830,657 shares, compared to its average volume of 6,390,577. The firm has a market cap of $147.70 billion, a price-to-earnings ratio of 79.89, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a fifty-two week low of $67.80 and a fifty-two week high of $107.17. The business has a 50 day moving average of $99.00 and a two-hundred day moving average of $94.55.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 1,201 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company's stock, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. This trade represents a 22.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,009 shares of company stock worth $14,407,381 over the last three months. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Royal Bank of Canada lifted their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Truist Financial decreased their target price on Boston Scientific from $120.00 to $113.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Barclays lifted their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Friday, January 10th. Finally, UBS Group lifted their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific presently has an average rating of "Buy" and an average target price of $110.22.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.